TUXUMDON POLIKISTIK SINDROMIDA STEROIDOGENEZNI BOSHQARISHDA INTRAOVARIAL OMILLARNING ROLINI OʼRGANISH
##article.subject##:
polikistik tuxumdonlar, bepushtlik, giperandrogenizm, hayz koʼrish disfunktsiyasi.##article.abstract##
Tadqiqotda asosiy guruhga 18 yoshdan - 35yoshgacha boʼlgan 215 ayol (oʼrtacha yoshi 25,8 ±3,28) tuxumdon polikistik sindromi (TPS) bilan ishtirok yetdi, va nazorat guruhiga 30 ayol yoshdagi mutlaqo sogʼlom ayollar kiritilgan. Korrelyatsiyalar tabiatini oʼrganish uchun oʼtkazilgan tadqiqotlar natijalari ingibin V (r=0,74; p˂0,05), АMG(r=0,79; p˂0,05), IPFR-I (r=0,67;p˂0,05), insulin (r=0,62; p˂0,05), indeks NOMА(r=0,66; p˂0,05) va LG darajasi TPS bilan ogʼrigan bemorlarda koʼrsatkichlari oʼrtasida sezilarli darajada ijobiy korrelyatsiyani aniqladik, salbiy teskari korrelyatsiya ingibin V (r=-0,7;p˂0,05), АMG (r=-0,73; p˂0,05), IPFR-I (r=-0,69; p˂0,05), insulin (r=-0,62; p˂0,05), NOMА indeksi (r=-0,67; p˂0,05) va FSG darajasi bilan. Yuqoridagilardan kelib chiqadiki, bu kasallikda tez-tez uchraydigan LG darajasining oshishi polikistik tuxumdonlar hujayralari tomonidan ingibin V, АMG va IPFR-I ishlab chiqarishni koʼpaytirishi va natijada androgenlar ishlab chiqarishni koʼpaytirishi mumkin, aftidan, umumiy salbiy taʼsir koʼrsatadi oddiy follikulogenez va ovulyatsiya, bu patogenez TPS baʼzi tuxumdon ichidagi omillar va tuxumdon steroidogenezi tizimlarining oʼzaro bogʼliq buzilishlarini oʼz ichiga olishi mumkinligini koʼrsatadi.
Библиографические ссылки
Гродницкая Е.Э., Щербатюк Ю.В., Бендусов И.А., и др. Антимюллеров гормон как маркер синдрома поликистозных яичников.// Проблемы репродукции. — 2013. — №6. — С.27-30.
Манухин, И.Б. Гинекологическая эндокринология. Клинические лекции: рук-во для врачей / И.Б. Манухин, Л.Г. Тумилович, М.А. Геворкян. – 3-е изд., перераб. – М.: ГЭОТАР-Медиа, 2013. – 272 с.
Московкина А.В. Оптимизация подходов к диагностике синдрома поликистозных яичников у девочек-подростков / А.В. Московкина, В.А. Линде, О.З. Пузикова // Таврический медико-биологический вестник. – 2016. – Т. 19, № 2. – С. 100-103.
Подзолкова, Н.М. Современные представления о синдроме поликистозных яичников / Н.М. Подзолкова, Ю.А. Колода // Фарматека. –2016. – № 3. – С. 8-15.
Azziz R, Carmina E, Chen Z et al. (2016): Polycystic ovary syndrome. Nature Reviews Disease Primers, 2: 16057.
Dumont, A.; Robin, G.; Dewailly, D. Anti-müllerian hormone in the pathophysiology and diagnosis of polycystic ovarian syndrome. Curr. Opin. Endocrinol. Diabetes Obes. 2018, 25, 377–384. [CrossRef]
Escobar-Morreale, Héctor. F (2018): Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, https:// doi. org/ 10. 1038/nrendo.2018.24.
F. Yang, Y.-C. Ruan, Y.-j. Yang et al., “Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women,” Reproduction, vol. 150, no. 4, pp. 289–296, 2015.
Gupta V and Mishra S (2017): L:A ratio, Insulin resistance and metabolic risk in women with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 11: S697–S701.
Kebapcilar A, Tatar M, Ipekci S et al. (2014): Cornea in PCOS patients as a possible target of IGF-1 action and insulin resistance. Archives of Gynecology and Obstetrics, 290(6): 1255–1263.
M.Hao,F.Yuan,C.Jinetal.,“Over expression of Lnkin the ovaries is involved in insulin resistance in women with polycystic ovary syndrome,” Endocrinology, vol.157, no.10, pp. 3709–3718, 2016.
Neven, A.C.H.; Laven, J.; Teede, H.J.; Boyle, J.A. A summary on polycystic ovary syndrome: Diagnostic criteria, prevalence, clinical manifestations, and management according to the latest international guidelines. Semin. Reprod. Med. 2018, 36, 5–12. [CrossRef] [PubMed]
Puche J and Castilla-Cortázar (2012): Human conditions of insulin-like growth factor-I (IGF-I) deficiency. Journal of Translational Medicine, 10(1): 224.
Richani D, Constance K, Lien S, et al. Cumulin and FSH cooperate to regulate inhibin B and activin B production by human granulosa-lutein cells in vitro. Endocrinology. 2019;160(4):853-862.
S. Cassar, M. L. Misso, W. G. Hopkins, C. S. Shaw, H.J.Teede,andN.K.Stepto,“Insulin resistancein polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies,” Human Reproduction, vol. 31, no. 11, pp. 2619–2631, 2016.
Tencer J, Lemaire P, Brailly-Tabard S, Brauner R. Serum inhibin B concentration as a predictor of age at first menstruation in girls with idiopathic central precocious puberty. PLoS One.2018;13(12):e0205810. https://doi.org/10.1371
Tokmak A, Bodur S, Erkilinc S et al. (2017): The Value of Prostate-Specific Antigen in Diagnosis of Polycystic Ovarian Syndrome in Adolescent Girls. Journal of Pediatric and Adolescent Gynecology, https:// doi. org/ 10. 1016/ j.jpag.2017.11.004.
Unfer V, Proietti S, Gullo G et al. (2014): Polycystic Ovary Syndrome: Features, Diagnostic Criteria and Treatments. Endocrinology & Metabolic Syndrome, 3(3): 1000136.
Yetim A, Yetim Ç, Baş F, et al. Anti-müllerian hormone and inhibin-a, but not inhibin-b or insulin-like peptide-3, may be used as surrogates in the diagnosis of polycystic ovary syndrome in adolescents: preliminary results. J Clin Res Pediatr Endocrinol. 2016;8(3):288-297. https://doi.org/10.4274/ jcrpe.3253.
